loncastuximab,lenalidomide,polatuzumab vedotin,axicabtagene ciloleucel,lisocabtagene maraleucel,vedolizumab,tafasitamab,selinexor
daiichi sankyo,karyopharm,overland adct biopharmaceuticals,gilead,takeda,mitsubishi tanabe,roche,bms,incyte,morphosys
[' vedo', 'dlbcl', 'selinexor', 'lenalidomide', 'axi-cel', 'liso-cel', 'polatuzumab', ' lena', 'loncastuximab tesirine', 'nhl', 'lymphoma', 'tafasitamab', 'imab ']
outstanding session on controversies in aggressive #nhl led by dr christopher flowers. very helpful insights on cns prophylaxis, r/r dlbcl and mcl #ash22 
Faculty @MayoClinic | HCT and cellular therapies | lymphoma| Trained @OUHealth and @MayoClinic, FL | Tweets are my own |